Automated Pap Smears Effect On Medicare Costs To Be Examined By IoM
This article was originally published in The Gray Sheet
The impact of automated Pap smear technology is among recent trends in the clinical lab industry that will be evaluated by a 12-member Institute of Medicine committee in a 15-month study of Medicare payment methods for laboratory tests.
You may also be interested in...
The Health Care Financing Administration needs to adopt principled methodologies for "gap-filling" and "cross-walking" in assigning pricing codes to new lab technologies in order to establish appropriate Medicare payment levels for new lab diagnostics, industry groups commented during an Institute of Medicine public meeting Jan. 20 in Washington, D.C.
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.